Share COVID-19 & the Health Care Industry Laura O'Dell, CFA and Chendhore Veerappan, PhD, CFA 13 April 2020 Health care analysts Chendhore Veerappan and Laura O’Dell discuss treatments health care companies are developing for COVID-19, how they’re ramping up testing capacity and what the virus means for health care holdings in our portfolios. The views expressed are those of Diamond Hill as of April 2020 and are subject to change. These opinions are not intended to be a forecast of future events, a guarantee of results, or investment advice. As of March 31, 2020 Diamond Hill owned Abbott Laboratories (equity), GlaxoSmithKline PLC (equity), Pfizer, Inc. (equity), Gilead Sciences, Inc. (equity), Roche Holdings AG (equity) and Thermo Fisher Scientific, Inc. (equity). As of January 31, 2020 Diamond Hill owned AbbVie, Inc. (debt) and Abbott Laboratories (debt).
The Global Economy in Review: Q1 2024's Winners, Losers and Surprises 23 April 2024 In Q1 2024, global markets showed mostly positive trends. The period continued to spotlight global monetary policy, suggesting its influence on market directions might be waning. Learn more in our latest commentary. (3 min read) Read
Resilient Labor Market, Stubborn Inflation Test Fed's Rate Cut Path 18 April 2024 Resilient labor market and stubborn inflation test the Fed's rate cut path. In our latest update, we discuss factors influencing the Fed’s decisions and how it’s impacting fixed income markets. (3 min read) Read